Mankind Pharma Ltd - Asset Resilience Ratio

Latest as of September 2025: 8.83%

Mankind Pharma Ltd (MANKIND) has an Asset Resilience Ratio of 8.83% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

Rs25.45 Billion
≈ $275.27 Million USD Cash + Short-term Investments

Total Assets

Rs288.13 Billion
≈ $3.12 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2019–2025)

This chart shows how Mankind Pharma Ltd's Asset Resilience Ratio has changed over time. See MANKIND financial flexibility index to measure the company's free cash flow as a share of total liabilities.

Liquid Assets Composition Over Time

This chart breaks down Mankind Pharma Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see MANKIND market cap overview.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Rs0.00 0%
Short-term Investments Rs25.45 Billion 8.83%
Total Liquid Assets Rs25.45 Billion 8.83%

Asset Resilience Insights

  • Limited Liquidity: Mankind Pharma Ltd maintains only 8.83% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Mankind Pharma Ltd Industry Peers by Asset Resilience Ratio

Compare Mankind Pharma Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Takeda Pharmaceutical Company Limited
F:TKDA
Drug Manufacturers - Specialty & Generic 0.69%
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131
Drug Manufacturers - Specialty & Generic 1.37%
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
Drug Manufacturers - Specialty & Generic 24.59%
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
Drug Manufacturers - Specialty & Generic 0.20%
Celltrion Pharm Inc
KQ:068760
Drug Manufacturers - Specialty & Generic 12.49%
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
Drug Manufacturers - Specialty & Generic 26.36%
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567
Drug Manufacturers - Specialty & Generic 0.00%
Zhejiang Anglikang Pharmaceutical Co Ltd Class A
SHE:002940
Drug Manufacturers - Specialty & Generic 9.11%

Annual Asset Resilience Ratio for Mankind Pharma Ltd (2019–2025)

The table below shows the annual Asset Resilience Ratio data for Mankind Pharma Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-03-31 6.09% Rs16.91 Billion
≈ $182.86 Million
Rs277.60 Billion
≈ $3.00 Billion
-0.15pp
2024-03-31 6.24% Rs7.46 Billion
≈ $80.72 Million
Rs119.63 Billion
≈ $1.29 Billion
-6.36pp
2023-03-31 12.60% Rs12.24 Billion
≈ $132.35 Million
Rs97.15 Billion
≈ $1.05 Billion
+1.92pp
2022-03-31 10.68% Rs9.77 Billion
≈ $105.63 Million
Rs91.48 Billion
≈ $989.29 Million
-18.15pp
2021-03-31 28.83% Rs18.37 Billion
≈ $198.70 Million
Rs63.73 Billion
≈ $689.18 Million
+11.91pp
2020-03-31 16.92% Rs8.58 Billion
≈ $92.82 Million
Rs50.73 Billion
≈ $548.66 Million
+16.32pp
2019-03-31 0.60% Rs246.21 Million
≈ $2.66 Million
Rs41.12 Billion
≈ $444.74 Million
--
pp = percentage points

About Mankind Pharma Ltd

NSE:MANKIND India Drug Manufacturers - Specialty & Generic
Market Cap
$11.03 Billion
Rs1.02 Trillion INR
Market Cap Rank
#2065 Global
#87 in India
Share Price
Rs2469.60
Change (1 day)
-4.13%
52-Week Range
Rs1927.40 - Rs2660.60
All Time High
Rs2998.40
About

Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory d… Read more